

**Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA):
Results from the GTH-AH 01/2010 Study**

Authors and affiliations

Katharina Holstein,¹ Xiaofei Liu,² Andrea Smith,² Paul Knöbl,³ Robert Klamroth,⁴ Ulrich Geisen,⁵ Hermann Eichler,⁶ Wolfgang Miesbach,⁷ Andreas Tiede⁸

- 1 Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 2 Biometry, Hannover Medical School, Hannover, Germany
- 3 Hematology and Hemostasis, Vienna Medical University, Vienna, Austria
- 4 Internal Medicine, Vivantes Clinic Friedrichshain, Berlin, Germany
- 5 Institute for Clinical Chemistry and Laboratory Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
- 6 Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg/Saar, Germany
- 7 Medical Clinic II, Institute of Transfusion Medicine, Goethe University, Frankfurt, Germany
- 8 Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Correspondence

Andreas Tiede (MD, PhD), Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Carl Neuberg Str. 1, 30625 Hannover, Germany, tel.: + 49-511-532-6287, fax: + 49-511-532-4146, email: tiede.andreas@mh-hannover.de

Study sites and investigators

Country and city (alphabetical)	Institution	Investigators
Austria		
Feldkirchen	Landeskrankenhaus	Alois Lang
Graz	Graz Medical University	Peter Neumeister
Salzburg	Paracelsus Medical University	Richard Greil
Vienna	Vienna Medical University	Paul Knöbl
Germany		
Berlin	Vivantes Hospital Friedrichshain	Robert Klamroth, Saskia Gottstein
Berlin	Charité University Hospital	Ulrich Kalus
Bielefeld	Evangelic Hospital	Klaus Leimkühler
Bonn	University Hospital	Johannes Oldenburg, Natascha Marquardt
Dresden	University Hospital	Uwe Platzbecker
Düsseldorf	Heinrich Heine University	Rüdiger E. Scharf, Barbara Bomke
Frankfurt	Johann Wolfgang Goethe University Hospital	Wolfgang Miesbach
Freiburg	University Hospital	Ulrich Geisen, Jürgen Heinz
Görlitz	Städtisches Klinikum	Kerstin Gutsche
Hamburg	Eppendorf University Hospital	Katharina Holstein
Hannover	Hannover Medical School	Andreas Tiede, Christiane Dobbstein
Heidelberg	SRH Kurpfalzkrankenhaus	Angela Huth-Kühne, Peter Staritz
Homburg/S.	Saarland University Hospital	Hermann Eichler, Joachim Schenk, Jürgen Groß, Bernhard Stephan
Jena	University Hospital	Kristina Schilling
Kiel	University Hospital Center Schleswig-Holstein, Campus Kiel	Ralf-Ulrich Trappe
Leipzig	Center of Coagulation Disorders, and St. Georg Hospital	Ute Scholz, Karin Liebscher
Lübeck	University Medical Center Schleswig-Holstein, Campus Lübeck	Ulrike Nowak-Göttl, Daniela Manner
Mainz	University Hospital	Inge Scharrer, Charis von Auer
Munich	Großhadern University Hospital	Michael Spannagl
Münster	Hemophilia Care Center	Hartmut Pollmann
Ravensburg	Oberschwabenklinik	Andreas Keßler
Regensburg	University Hospital	Stephanie Meyer
Ulm	University Hospital	Sabine Struve
Wiesbaden	German Diagnostic Clinic	Manuela Krause
Würzburg	University Hospital	Udo Steigerwald

Table S1: Fatal bleeds

Patient	Location	Bleed start	Day of death	Cause of death
003-04	Upper extremity, fasciotomy	Day 1 and Day6	Day 7	Bleeding, Infection
006-07	Tongue and throat	Day 15	Day 23	Aspiration
019-02	Intracranial	Day 26	Day 43	Cerebral oedema

Table S2: Factors influencing the rate of new bleeds, limited to those treated with bypassing agents or factor VIII concentrates, after day 1

Parameter	Adjusted IRR (95% CI)	P value
FVIII activity category		
<1%	7.3 (2.2-25)	0.0015
1-<5%	9.1 (2.7-30)	0.0003
5-<20%	8.3 (2.6-26)	0.0003
20-<50%	6.3 (2.0-20)	0.0014
≥50%	1	
WHO performance status		
0 (best)	0.24 (0.07-0.86)	0.0280
1	0.62 (0.25-1.55)	0.3067
2	0.52 (0.19-1.40)	0.1976
3	0.75 (0.30-1.89)	0.5411
4 or 5 (worst)	1	
Other baseline conditions		
Renal insufficiency	1.74 (0.93-3.27)	0.0832
Diabetes mellitus	1.09 (0.56-2.11)	0.7993
Time (per week)	0.72 (0.62-0.83)	<0.0001

Adjusted incidence rate ratios (IRR) from generalized linear mixed model of weekly bleeding rate (dependent variable, utilizing negative binomial distribution and log link function) with indicated parameters. Only treated bleeds were considered instead of all bleeds (compare Table 2 of the main paper). Abbreviations: IRR, incidence rate ratio; WHO, World Health Organization.

Table S3: First line dosing information on 48 bleeds treated with rFVIIa

	Severe N = 26	Non-severe N=22	P
Starting dose in $\mu\text{g}/\text{kg}$ – mean (SD)	95.8 (20.1)	85.4 (13.5)	0.0448*
Dosing interval – n (%)			0.0092‡
2 h	6	1	
3 h	9	5	
4 h	6	5	
8 h	-	3	
12 h	3	2	
24 h	2	-	
Single dose only	-	6	

This analysis comprises all bleeds, to which rFVIIa dosing information could be unambiguously assigned. Bleeding events with multiple simultaneous bleeds or overlapping bleeding events were excluded.

* Unpaired t test

‡ Chi square test for trend

Table S4: Hemostatic treatment information: patient level

Doses are for: rFVIIa in mg; APCC in units; hFVIII in international units; fibrinogen concentrate (fbg.) in g; fresh frozen plasma (FFP), packed red blood cells (PRBC) and platelet concentrates (PC) in units; tranexamic acid (TXA) in mg.

ID No.	Body weight	Total bleeds	rFVIIa	APCC	hFVIII	FFP	Fbg.	PRBC	PC	TXA
1	85	1	7							
2	66	1								
3	69	2	26		5000			8		15000
4	82	4	2555	340000				24		
5	48	5	610					32		
6	70	4								
7	69	4	1208					29		12000
8	95	4	491	495000				74		
9	70	3	686	204000				24		
10	80	2	917							
11	71	1						1		
12	70	0								
13	96	2	56	101000						
14	75	2	120							
15	90	4	1168							
16	95	1	384							
17	60	0								28000
18	71	3	14							45000
19	NR	0								
20	50	3	25							
21	80	8	14	4000						
22	76	3	56							
23	76	1								
24	79	2								
25	55	1	80	86000						
26	83	4		62000						60000
27	80	1	80							4000
28	75	0								25250
29	66	1		63000				16		
30	70	3	104							76000
31	66	1						4		
32	62	0						4		
33	46	1	8	9000				1		
34	82	2	91	9000	133000			13		
35	60	5	265	27000	107000			88		
36	72	2			10000					
37	80	1	168		45000			4		
38	62	4	695		580000			16		
39	31	3	5	102000	35000		52	52	2	42000
40	64	3	315	48000	36000			44		
41	77	1		66000						
42	51	1		3000	44000					
43	80	0								
44	64	1	54		140000					
45	71	2	36		33000			4		
46	70	2	25					12		72000
47	88	1								
48	72	1	172					4		
49	72	1	820		2000	16		86	20	
50	115	8								
51	99	5	195					8		16500
52	85	2	467					65	4	
53	80	7	19		18000			2		
54	113	9								
55	78	4								
56	82	2								
57	83	3								

ID No.	Body weight	Total bleeds	rFVIIa	APCC	hFVIII	FFP	Fbg.	PRBC	PC	TXA
58	85	1			202000					
59	90	6								
60	77	2	28	68000						18000
61	NR	3	70					16		
62	85	5	693	28000				45		
63	61	4	197	58000						
64	78	2								
65	100	3	126							54000
66	83	4		302000						24000
67	80	2	301							60000
68	62	4								30000
69	82	7	296	52000						93000
70	65	7	408					47		105000
71	64	4								45000
72	75	3	90	138000				391		28000
73	81	6	224					20		90000
74	70	3								20000
75	84	6	326							
76	70	8	1379					20		21000
77	73	2	133					4		13500
78	79	2	210					4		
79	74	3	1420					25		
80	88	1	1021					4		
81	80	1								500
82	85	0	130					20	12	
83	85	5	750					20		
84	NR	0								
85	117	3	460	10000						
86	105	1	28			20		30		51000
87	80	3	80							
88	90	1	24					1		
89	72	2								
90	100	2	386					9		
91	75	1								
92	63	7	372					6		
93	68	4								
94	72	1	252					17		
95	98	1	258		7000			4		
96	75	3								
97	60	2								750
98	112	8	1120					12		260000
99	85	7	1264					4	1	108000
100	66	3	300			68		212	14	28000
101	102	0								
102	90	4				9		8		18000